About

Science

Learn how we are advancing our pipeline.

About Hypertrophic Cardiomyopathy (HCM)

Moving crowd with blurs of motion.
Two people kayaking on water together.
Two people holding hands walking.

HCM is a disease of excessive heart contraction and impaired relaxation.

In hypertrophic cardiomyopathy (HCM), overactive myosin causes the myocardium to abnormally thicken. This can lead to declining cardiac performance, or how well the heart fills with and pumps blood. Symptoms can include shortness of breath, chest pain, fatigue, and fainting, which typically worsen with physical activity.

There are two kinds of HCM.

Patients can have either obstructive HCM (oHCM) or non-obstructive HCM (nHCM). In obstructive HCM, the thickened muscle impedes blood flow out of the heart causing obstruction at the left ventricular outflow tract (LVOT).

In both forms of HCM, the thickened myocardium makes it harder for the heart to contract and relax.

HCM is among the most common rare diseases.

HCM affects approximately 1 in 500 individuals in the United States. Even with the approval of targeted therapies in oHCM that have corresponded to an increase in diagnoses, HCM remains severely underdiagnosed. Many patients encounter delayed diagnosis whereas most remain frequently undiagnosed and/or misdiagnosed.

Unmet Needs

While recent advances have introduced new treatment options, many patients and clinicians continue to face challenges with complex dosing requirements and intensive monitoring protocols. Fewer than 20% of eligible oHCM patients in the US have been treated to date with targeted therapies.

Non-obstructive HCM remains an underdiagnosed condition with no approved targeted treatment options. There is a significant need for therapies that can deliver meaningful improvements with greater convenience and accessibility.

About BHB-1893

BHB-1893 is a selective, reversible small-molecule cardiac myosin inhibitor with rapid onset of action, favorable safety, and potential greater convenience. It was designed to address limitations of existing treatments through three key advantages:

Efficacy
Safety
Convenience

More than 250 clinical study participants have received BHB-1893 to date, whose experiences constitute a growing safety database.

Pipeline

Braveheart is advancing BHB-1893 through global late-stage clinical development, seeking to determine its potential as a convenient treatment requiring minimal or no dose titration.

Interested in joining our team?

Learn more about our openings.

Learn More